Bone Biologics Selects Cytovance(R) Biologics for cGMP Manufacturing of its Breakthrough Bone and Cartilage Regeneration Therapy.

OKLAHOMA CITY -- Cytovance([R]) Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Bone Biologics, Inc. to its diverse and growing client portfolio. Bone Biologics has selected Cytovance for process development and cGMP manufacturing of its breakthrough recombinant protein for spinal fusion surgery.

"We selected Cytovance as our manufacturing partner after an exhaustive industry search and qualification process," said Bruce A. Hazuka, president and chief executive officer of Bone Biologics. "Cytovance earned our business by providing a unique blend of technical expertise, responsiveness and operational flexibility that will facilitate the rapid development of our platform technology into phase I clinical trials for our initial market focus of bone regeneration."

The Bone Biologics' project is being executed out of Cytovance's multi-product cGMP production facility in Oklahoma City. The 44,000 sq. ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production. Cytovance specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from both fed-batch and perfusion processes.

"We are very pleased to work with Bone Biologics and play a role in the advancement of their breakthrough work in bone and cartilage regeneration," said William Canfield M.D. Ph.D., chairman of Cytovance Biologics. "This contract validates our business model and value proposition of offering a comprehensive package of services and state-of-the-art facilities."

Cytovance was founded to help biopharmaceutical companies advance recombinant protein and antibody products rapidly and cost-effectively from the bench, through clinical development and into the international marketplace The company's approach couples considerable client-side experience with the necessary technical and operational expertise to deliver effective processes, products and the supporting know-how that meet international regulatory standards and facilitate efficient completion of clinical development.

About Bone Biologics

Bone Biologics is a convergence Biotechnology Company focused in the Orthobiologics space. The Company was founded by University of California, Los Angeles (UCLA) professors in 2004. The target markets for the unique UCB-1TM protein-based technologies of the Company are bone and cartilage regeneration. The Platform Technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Lead product development and clinical studies are targeted on spinal fusion surgery, a rapidly growing market space currently underserved by outcome enhancements. The UCB-1TM technology has met and surpassed existing standards of care outcomes in ongoing studies. For more information, visit www.bonebiologics.com.

About Cytovance Biologics

Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture. An experienced management team formed the company to address the biotechnology industry's increasing needs for full-service manufacturing capacity at the clinical and early commercial scale. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City, Okla. facilities. For more information on Cytovance, visit www.cytovance.com.